OncoCyte (NYSEAMERICAN:OCX) Coverage Initiated by Analysts at Needham & Company LLC

Needham & Company LLC started coverage on shares of OncoCyte (NYSEAMERICAN:OCX) in a research report sent to investors on Tuesday morning, TipRanks reports. The firm issued a buy rating and a $4.00 target price on the biotechnology company’s stock.

A number of other brokerages have also issued reports on OCX. Chardan Capital lowered shares of OncoCyte from a buy rating to a neutral rating and reduced their target price for the stock from $7.75 to $2.00 in a research report on Tuesday. Lake Street Capital lowered their target price on shares of OncoCyte from $6.00 to $4.00 and set a buy rating for the company in a research note on Tuesday. Piper Sandler downgraded shares of OncoCyte from an overweight rating to a hold rating in a research note on Tuesday. Finally, Zacks Investment Research cut shares of OncoCyte from a hold rating to a sell rating in a report on Tuesday, June 16th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. The stock currently has an average rating of Hold and a consensus target price of $4.05.

NYSEAMERICAN:OCX opened at $1.91 on Tuesday. OncoCyte has a 52-week low of $1.50 and a 52-week high of $3.51.

OncoCyte (NYSEAMERICAN:OCX) last posted its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). The firm had revenue of $0.02 million for the quarter.

In related news, major shareholder Broadwood Partners, L.P. bought 1,050,000 shares of the business’s stock in a transaction dated Friday, April 24th. The stock was bought at an average price of $2.24 per share, for a total transaction of $2,352,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

A number of institutional investors have recently modified their holdings of the business. State Street Corp raised its stake in OncoCyte by 3.4% in the 4th quarter. State Street Corp now owns 435,208 shares of the biotechnology company’s stock worth $979,000 after purchasing an additional 14,375 shares in the last quarter. P.A.W. Capital Corp raised its stake in OncoCyte by 40.0% in the 1st quarter. P.A.W. Capital Corp now owns 350,000 shares of the biotechnology company’s stock worth $858,000 after purchasing an additional 100,000 shares in the last quarter. Geode Capital Management LLC raised its position in shares of OncoCyte by 4.7% in the 1st quarter. Geode Capital Management LLC now owns 327,358 shares of the biotechnology company’s stock valued at $802,000 after buying an additional 14,593 shares in the last quarter. Phoenix Holdings Ltd. acquired a new position in shares of OncoCyte in the 1st quarter valued at approximately $628,000. Finally, Penbrook Management LLC raised its position in shares of OncoCyte by 21.9% in the 1st quarter. Penbrook Management LLC now owns 215,625 shares of the biotechnology company’s stock valued at $529,000 after buying an additional 38,747 shares in the last quarter.

About OncoCyte

OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.

Featured Article: Gross Domestic Product (GDP)

Analyst Recommendations for OncoCyte (NYSEAMERICAN:OCX)

Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.